RPOBiosafety Oversight | IBC Policies and Procedures


Search for a Word

To search for a word use the keyboard shortcuts CTRL-F or F3. Mac users should use Apple's Command key () + F.


Table of Contents



1. Mission Statement

The University of Vermont (UVM) Institutional Biosafety Committee (IBC) is a standing committee that ensures that all research and teaching activities involving biohazardous materials are conducted in a safe and informed manner. The IBC is responsible for ensuring full compliance with the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) and for monitoring all other research and teaching activities involving the use of infectious or potentially infectious biological materials and biotoxins. The IBC reviews all research and teaching protocols that involve the following materials without regard to the source of funding:

  • Recombinant or synthetic nucleic acid molecules as specified in the NIH Guidelines
  • Human, animal, and plant pathogens (bacteria, fungi, viruses, parasites, prions)
  • Plasmid vectors
  • Viral vectors
  • Human-derived materials (blood, blood products, cells, tissues, and clinical specimens) when used in conjunction with recombinant or synthetic nucleic acid molecules
  • Biotoxins
  • Select Agents and Toxins

The materials listed above will hereafter be referred to in this document as “biohazardous materials” or “materials”.

This document outlines the policies and procedures that must be followed when using or storing biohazardous materials.  Since laboratory work can involve exposure not only to these biohazardous materials, but also to other biohazards, chemical and radiological hazards, these policies should be used in conjunction with other pertinent University policies.  See Radiation Safety Committee and UVM’s Environmental Health and Safety Committee web pages for more information.


Back to Top


1.1 Introduction to the Committees

The Institutional Biosafety Committee (IBC) at the University of Vermont (UVM) serves the UVM community.  The IBC is responsible for review of research projects and teaching-related activities to ensure that recombinant or synthetic nucleic acid molecules, infectious agents and biological toxins are handled appropriately at UVM. 

The IBC Policy and Procedure Committee, which includes Committee leadership, Biosafety Professionals, and IBC staff, convenes monthly to review changes in policy and procedures and new regulations.

Ad-hoc Noncompliance Subcommittees, including a subset of the members and other institutional personnel as applicable, are convened as necessary to review noncompliance cases. 

Institutional Review Entity (IRE) is convened when a project appears to be Dual Use Research of Concern as outlined in Section 3.10 of this document.  This review body consists of various constituents across campus as outlined in Section 3.10.


Back to Top


1.2 Governing Principles

The NIH Office of Science Policy is where the IBC turns when developing local procedures and policies.  Two primary resources are listed below:

NIH Guidelines Web Page

This page provides up-to-date NIH news, register notices, director’s statements, etc.  This is also where the latest NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) is found.  The Guide requires that each institution establish an Institutional Biosafety Committee with the authority to approve proposed research projects and teaching activities involving recombinant or synthetic nucleic acid molecules.  The Guide details safety practices and containment procedures for basic and clinical research involving recombinant or synthetic nucleic acid molecules, including the creation and use of organisms and viruses containing recombinant or synthetic nucleic acid molecules. 

Centers for Disease Control and Prevention (CDC)

The CDC in collaboration with NIH published the Biosafety in Microbiological and Biomedical Laboratories (BMBL), 5th Edition.  This document contains guidelines for microbiological practices, safety equipment, and facilities that constitute the four established biosafety levels. The BMBL is generally considered the standard for biosafety.


Back to Top


1.3 Scope of Authority

The President of the University has delegated the authority to the Vice President for Research Administration as the lead Institutional Official responsible for the assurance of compliance in the biosafety area.  The IBC policies apply to activities involving the use of biohazardous materials in research projects and applicable teaching laboratories.  It applies to research and teaching activities that are:

  • Sponsored by UVM,
  • Conducted by UVM researchers,
  • Classes taught by UVM faculty, or
  • Conducted using UVM’s property, facilities, or non-public information.

All faculty, staff, students, and visitors are included within the scope of these IBC Policies.
The IBC is delegated the authority to:

  1. Define the basic policies, procedures and standards as required by NIH to oversee the safe use of biohazardous materials.
  2. Review requests for the use of these materials for compliance with NIH Guidelines and the BMBL, and approve those requests which are found to conform. As part of the review process, the IBC will do the following, as applicable:
    • Conduct an independent assessment of the containment levels, as required by the NIH Guidelines for research involving recombinant or synthetic nucleic acid molecules. 
    • Conduct an assessment, if applicable, of the facilities, procedures, practices, training, and expertise of personnel involved in the requested use of these materials.
    • Ensure compliance with all surveillance, data reporting, and adverse event reporting requirements set forth in the NIH Guidelines.
  3. Disapprove, terminate, or suspend activities involving these materials which are not in conformity with the Guidelines;
  4. Notify investigators in writing of its decision to approve or withhold approval of activities involving these materials, or of modifications required to secure IBC approval.  All decisions will be part of the IBC records maintained by the Research Protections Office;
  5. Set containment levels as specified in the NIH Guidelines;
  6. Conduct periodic review of the use of these materials to ensure that the requirements of the Guidelines are being fulfilled;
  7. Consult with the Biosafety Officer in maintaining and following emergency plans covering accidental spill and personnel contamination resulting from use of recombinant DNA, infectious agents or biological toxins;
  8. Report to the Vice President for Research Administration any significant related illness or accident resulting from use of these materials that appears to be a hazard to public health;
  9. Report to the Vice President for Research Administration and the Office of Science Policy (OSP) any significant problems with or violation of the Guidelines;
  10. The IBC may not authorize initiation of experiments not explicitly covered by the Guidelines until NIH establishes the containment requirement.

Institutional Relationship


Back to Top


1.4 Committee Membership

The IBC is responsible to the Vice President for Research Administration (VPR).  The IBC is provided administrative staff from the Research Protections Office (RPO).

The IBC is registered with the National Institutes of Health (NIH) Office of Science Policy (OSP). An annual report is filed with OSP, which includes an updated list of IBC members indicating the role of each member and biosketches for each member. 

Committee member appointments are delegated by the Institutional Official to the Executive Director of Research and Integrity.


  • A Committee Chair must be a University faculty Member and must have prior service as a Committee Member.
  • It is the responsibility of the Committee Chair to conduct Committee meetings in accordance with established federal regulations and University operating policies and procedures.  These responsibilities, include but are not limited to the following:
    • sign official Committee action documents or designate an IBC Member to do so;
    • keep abreast of relevant state and federal regulations;
    • meet as needed with the Research Protections Office Director (RPO) and/or Institutional Official to discuss Committee activities;
    • meet regularly with appropriate representatives of the RPO and the Environmental Health and Safety Office to coordinate the review of  biohazardous materials throughout the University;
    • recommend, in consultation with the RPO Director, new Members to the Institutional Official;
    • ensure that new Members are properly oriented to and educated about their duties and responsibilities;
    • initiate activities designed to keep the campus and community apprised of IBC activities; and
    • assist appropriate University administrators in the preparation of federal reports and assurances and meet with inspectors/site visitors as necessary.
    • No method for removal is delineated, as all Members are appointed and serve at the discretion of the Vice President for Research Administration.
    • The Chair is appointed for renewable two-year terms.

Associate Chair
An Associate Chair is nominated by the Chair from among Membership of the IBC. Responsibilities of the Associate Chair are to

  • conduct the meetings of the IBC in the absence of the Chair or if there is a conflict of interest by the Chair's participation,
  • sign official Committee action documents and approve Committee actions as delegated by the Members or by designation of the Chair;

The Associate Chair is appointed for renewable two-year terms.

General Committee Membership

  • Members will be of varying professional and personal backgrounds and must demonstrate a genuine interest in and commitment to the purpose of the Committees.  Specific Membership criteria will comply with all relevant federal and state regulations. 
  • When vacancies occur, suggestions for Membership will be sought, after which formal recommendation(s) for new Member(s) will be made by the Committee Chair and the RPO Director to the Executive Director of Research and Integrity. 
  • The Executive Director of Research and Integrity will in no case make a final appointment without prior consultation with the Committee Chair and the RPO Director.
  • Committee appointments will usually be for renewable two-year terms, serving at the discretion of the Executive Director of Research and Integrity.
  • Consideration is given to achieve a balance between new and experienced Members when determining which appointments will be renewed.
  • Effort will be made to consider gender and cultural diversity.
  • No specific attendance requirements are delineated.
  • No method for removal is delineated, as all Members are appointed and serve at the discretion of the Institutional Official.      

Regular Voting Member
At a minimum the Committee will consist of not less than five regular voting Members and at a minimum will include the following:

  • One or more individuals with expertise in recombinant DNA technology, infectious agents, and/or biological safety, and/or physical containment.
  • At least two members who are not affiliated with UVM (including family members) and who represent the interests of the surrounding community with respect to health and protection of the environment.
  • At least one individual with expertise in plant, plant pathogen, or plant pest containment principles before reviewing and approving experiments involving plants with biosafety level 2 or greater.
  • At least one scientist with expertise in animal containment principles before reviewing and approving experiments involving animals with biosafety level 2 or greater.

In addition, it is recommended that the membership include:

  • An individual representing laboratory technical staff;
  • And an individual with expertise in radiation safety

An individual who meets the requirements of more than one of the categories detailed above may fulfill more than one requirement, as long as the minimum number is met. 

Ex Officio Members
An ex officio member is defined as a member who serves by virtue of an office or position held.  An ex officio member may be appointed by the Institutional Official as a voting member or a non-voting member.

Alternate Members
The RPO Director and Assistant Directors will serve as alternate voting members. 

Ad Hoc Reviewers
The Committees may, at their discretion, obtain consultation from individuals with expertise in specialized areas, such as gene therapy or biosecurity, to assist in the review of complex issues which require expertise beyond or in addition to that available on the IBC. The IBC shall consult with General Counsel and other University Officials, as indicated, to address issues pertaining to institutional policies, applicable law, and standards of conduct and practice. These individuals are not allowed to vote.

Biological Safety Officer
A Biological Safety Officer has been appointed.  This is a NIH required appointment based on current BSL-3 activities.  

Regular membership on the IBC will be without monetary compensation.

Legal Implications of Membership 
Actions by the Members carried out as a function of their Committee appointments are included under the University's general liability insurance coverage.

Institutional Review Entity (IRE)

An IRE will execute the institutional review of research identified as Dual Use Research of Concern (DURC).  See Section 3.10 for the organizational framework for oversight of DURC.  

Standing or Ad Hoc Sub-Committees
These types of Sub-Committees may be appointed by the Chair with specific goals and purposes consistent with the responsibilities of the IBC (e.g. Policy and Procedure, non-compliance cases, as required).

Conflict of Interest
If an IBC Member has a conflicting interest in a protocol (including, but not limited to being a principal investigator, a co-investigator, or a consultant on that protocol), that Member may only provide information as requested by the IBC and will not be assigned to officially review nor vote on that protocol.

Committee Member Training
New Members meet with the Chair and the Biosafety Officer for training and basic introductory materials are provided to acquaint the new Member with the Committee and its functions prior to participation in a meeting.  Additional materials are provided for reference during protocol review.

Code of Conduct For Committee Members
This Code of Conduct is a set of behavioral expectations intended to assure that our Committee members uphold the highest level of integrity and ethical standards.  Members must not discuss, disclose, or reproduce any protocol-related information, except as necessary to carry out responsibilities or as required by law.  Members must limit their electronic access to that which is required to fulfill their Committee duties.  Members must never access any research protocols to satisfy personal interest or curiosity.


Back to Top


1.5 Public Records and Open Meeting (Vermont Law)

Federal Freedom of Information Act (FOIA)
The Freedom of Information Act (FOIA) is a federal law that generally provides that any person has a right, enforceable in court, to obtain access to federal agency records.  FOIA applies only to federal agencies.  Each state has its own public access laws that are consulted for requests for access to state and local records. 

Vermont Public Records Act
State open records laws are state statutes that govern access to records in the possession of state and local governments and other state public bodies, such as public universities.

The University of Vermont is a public body subject to the Vermont Public Records Act (1 V.S.A. §316)(a). Under this statute, any person may inspect or copy any public record of a public agency. The definitions of public agency; public records and documents are included in 1 V.S.A. §317.

Vermont State Exemptions to FOIA
Vermont statute exempts research data and protocols under §317(c)(23). Because these records are exempt from public disclosure by the State, the FOIA cannot be employed to inspect or copy records. Researchers should forward any request for inspection or copies of research records to the Vice President for Executive Operations according to the UVM Records and Document Request policy.

Vermont Open Meetings Law
The University of Vermont is a public body subject to the Vermont Open Meetings law §312. All meetings of a public body are declared to be open to the public at all times, except when the meeting moves into Executive Session to discuss research protocols provided in §313.

Executive Session Exemption under the Vermont Open Meeting Law
The Committee may only move into Executive Session to consider research protocols as exempted under §317(c)(23).

The Committees’ convened meetings begin in Open Session and move into executive session only after an affirmative vote of two-thirds of its present members. Such vote is taken in the course of an open meeting and the result of the vote recorded in the minutes. A motion to go into executive session must indicate the nature of the business of the executive session, and no other matter may be considered in the executive session.  No formal or binding action will be taken in executive session.  Once protocol discussions are complete, the Committee will vote to move back into Open Session to collect a formal vote on the research protocols that were discussed.


Back to Top


1.6 Electronic Review and Signatures

All reviews, initial, continuing and amendments are reviewed electronically by the IBC members as assigned.  Members receive an email notice that a review is pending.  They proceed to the electronic record by either utilizing a link embedded within the email or they proceed directly to the system home screen where they will find their review task(s).  Members are required to authenticate into Click using their UVM NetID and password prior to completing their review.  Each electronic review is stamped with the name of the individual carrying out the review activity (electronic signature), and the time and date that the electronic signature was applied to the review.


Back to Top


2. Operations of the IBC

The IBC will follow these operating procedures.  These procedures will be reviewed periodically, at least once every three years, to ensure compliance with all pertinent laws governing the use biohazardous materials.  Changes to these operating procedures will be developed in consultation with the RPO and the UVM Environmental Health and Safety Office and will be reported to the Institutional Official. 
The institution will provide the IBC with resources, office space, professional staff, and support staff sufficient to carry out their responsibilities efficiently and effectively and to serve as day-to-day liaison with appropriate University administrative offices, project investigators, other institutional safety and ethics boards, and various regulatory and funding agencies.

Convened Meetings

The Committees meet monthly if there are agenda items. 

Meeting Notices

Meetings are noticed on the IBC website in conformance with the Vermont Open Meetings Law (1 V.S.A. Section 310) while affording researchers with the protections of the Vermont Public Records Act Law (1 V.S.A. Section 316).  The agenda, including the time and location of the meeting, are distributed in advance to all members.  All pre-meeting protocol materials are located within the electronic submission and review system.  All members have access to this system.

Conducting Initial and Continuing Review

Initial and continuing IBC reviews and approvals of a Master Protocol Registration (MPR) will occur in compliance with NIH Guidelines. Continuing reviews will be preceded by IBC receipt of an appropriate progress report from the investigator.  Reviewer forms and internal checklists are utilized as a guide to ensure that these criteria have been met.

Review Decisions and Process for Appeal

Review decisions will be forwarded to the researcher in writing.   Review decisions may not be overridden.  However, the Vice President for Research Administration shall have the final authority to disapprove, restrict or terminate a study which has received IBC approval. There is no process delineated for appeal of Committee decisions. However, there is no prohibition for resubmission of specific requests or protocols for additional review by the Committee.

Protocols Requiring More Frequent Review

Determination of which studies require review more often than annually is done at the time of protocol review, on a case by case basis, depending upon protocol specific factors, including, but not limited to, the level of risk.

Modification to a MPR

The IBC requires that changes in approved research be reviewed prior to initiation.  Changes implemented prior to Committee approval is considered noncompliance.


The IBC is required to report significant problems, violations of the NIH Guidelines, or any significant research-related accident or illness by the Institution. See section 4.4 for further details.

Removal from Consideration

RPO staff will have the authority to remove from further Committee consideration, a study which has obtained initial approval, when the PI fails to respond to ongoing clarifications or training requests. The PI will be required to close the study in UVMClick-IBC.


The IBC, through the administrative staff, is responsible for reporting findings, actions as well as requesting clarifications to the investigators in writing, and to the appropriate offices within the institutions’ administration through reports and meeting minutes to institutional officials through their representatives on the Committee, and to sponsors of research, if so required.

Authority to Sign IBC Documents

a. Results of Reviews, Actions and Decisions whether Full or Expedited

Depending upon the nature of the required conditions, the IBC designates any of the following individuals or groups of individuals to determine that the conditions of approval have been satisfied:

  • The IBC chair;
  • Another member;
  • An IBC Analyst/Member or;
  • Other qualified IBC administrative staff person, who need not be an IBC member.

Individuals designated by the IBC must have appropriate expertise or qualifications. For some conditions, the review of response materials from investigators will require scientific or other technical expertise. In such cases, the IBC Chair will review the responsive materials or designate another individual who has the appropriate expertise.

Follows are some examples of conditions in which IBC Analysts/Members have been designated to review and approve response materials.

  • Correction of minor grammatical and typographical errors in the MPR;
  • Requirement to revise the protocol in a specific manner as dictated by the Committee.

b. Administrative Review and Approval

Administrative items are reviewed and approved by IBC Analysts/Members or appropriate IBC staff. IBC Analysts/Members may consult with the Committee chair prior to approval. Below are examples of administrative items.

  • Correction of omission of sponsor
  • Changes to Key Personnel
  • Continuing Reviews (IBC Analyst)

c. Routine Internal Correspondence

Any action, letter, memo or e-mail between the Committee or IBC staff and the faculty or staff of the University that provides information concerning the review of research protocols by the Committee or IBC staff and which do not imply or appear to imply approval of this activity may be signed by the staff member.

d. Decisions Made by the Chair

Any letters, memos or email sent representing the decision or opinions of the Chair or Vice Chair of the IBC, as long as such correspondence does not imply review and approval, may be signed by IBC staff if so designated by the IBC.

Electronic Reviews

All reviews, initial, continuing reviews and modifications are completed electronically by the IBC members as assigned. Members receive an email notice that a review is pending. Members are required to authenticate into the electronic system using their UVM NetID and password prior to completing their review. The system validates the member’s authentication credentials based upon the member’s role in the system and determines available actions for each person. The electronic review is stamped within the system with the name of the individual carrying out the review activity (electronic signature), and the time and date that the electronic signature was applied to the review.

Members only access records that they have been assigned to review.

Voting Requirements

1. Definition of Quorum: A majority of the total number of regular voting members will constitute a quorum. If less than a majority of the total number of regular voting Members is present, if an ex officio nonvoting member(s) is available, that individual may be included to constitute a quorum.  If a quorum is lost at any time during the meeting, the meeting shall be adjourned and no further action taken until a quorum is attained.
2. Official Committee action (non-exempt) on new MPRs involving biohazardous materials will be by formal vote (exceptions previously noted under E.4) at convened meetings of a quorum of Committee members.
3. All meetings will be conducted using Robert’s Rules of Order as guidance, with deviations made as deemed appropriate by the Chair.
4. Selection of specific protocols for review by members is determined by the Committee's administrative staff and/or Chair.  If an IBC member has a conflicting interest in a MPR (including, but not limited to being a principal investigator or a co-investigator) that member may only provide information as requested by the IBC and will not be assigned to officially review nor vote on that protocol.
5. IBC members may participate in a convened meeting of the IBC via telephone or video conferencing.  Those members have access to the research protocol materials in advance of the meeting within UVMClick-IBC.

IBC Record Requirements

The IBC keeps all records in accordance with all pertinent regulations. This record keeping includes the following.

Membership rosters - The institution is required to maintain a current list of IBC members identified by name; earned degrees; representative capacity; indications of experience such as board certifications or licenses sufficient to describe each member's chief anticipated contributions to IBC deliberations; and any employment or other relationship between each member and the institution, for example, full-time employee, part-time employee, member of governing panel or board, stockholder, paid or unpaid consultant. UVM rosters indicate regular voting versus alternate members, as well as alternate replacement assignments. Rosters are updated each time there is a change in the Committee membership. Copies of curriculum vitae are obtained and kept on file for all primary and alternate members.
Written procedures and guidelines including, but not limited to, the Research Manual and all website content.
Minutes of meetings document

  • attendance of members, consultants, and guests
  • discussion of controverted issues,
  • actions taken,
  • basis for requiring changes in research or disapproving research,
  • a record of voting (for, opposed, abstaining, recusal),
  • members arriving and leaving the meeting once the meeting is called to order,
  • names of members who recuse themselves because of a conflict of interest along with the fact that a conflict is the reason for the recusal,
  • which alternate member is replacing a primary member,
  • a record and vote of members who participated in the convened meeting via phone or video conferencing.Approved minutes will be signed by the Chair or designee, scanned, and maintained as a PDF in a shared electronic file.

A report of business conducted by the designated review process is available in the UVMClick-IBC system.

Protocol/MPR files are either in paper or electronic form. Both the paper and the electronic files include protocols, continuing reviews, amendments, risk assessments, and reported incidents. Once closed, any paper files are stored off-site and can be retrieved within 24-48 hours. Protocol files, whether paper or electronic will be destroyed after the protocol has been closed for at least three years.

Communications to and from the IBC are maintained in the protocol file.


Back to Top


2.1 Types of Committee Review

The IBC will review and have authority to approve, require modifications in (to secure approval), or disapprove all research and teaching activities involving biohazardous materials. These review categories are employed for new master protocol registrations (MPR), amendments to add new projects to existing registrations, and continuing review. 

Preliminary Reviews

In all cases, there are two preliminary reviews that require completion prior to review by the Committee. 

Biological Safety Officer Review (BSO)

Prior to any type of Committee review, MPR materials must be submitted into the UVMClick system where they will be forwarded to the BSO for review. The BSO or designee will conduct a risk assessment. The risk assessment document will be forwarded electronically back through the system.

IBC Analyst Pre-Review

The IBC must receive sufficient information regarding proposed activities to make the determinations as required by regulations.  After BSO Review is complete, the IBC Analyst will conduct a pre-review of submitted materials.  A new MPR or amendment to add a new project to an existing MPR will not be added to an agenda until both of these reviews are complete.    A specific regulatory checklist is followed to determine if the submission is ready for review. If the submission is incomplete or lacks information necessary to conduct a review, it will not be reviewed until the information is provided.  Once determined to be satisfactory the review will continue.

Committee Review (convened meeting)

The IBC employs the convened meeting review process for review and approval of submissions that propose to use non-exempt biohazardous materials in a risk category greater than or equal to Biosafety Level 2 (BSL2).

Notification to Research Community
Committee meetings are noticed on the Committee website. Submissions are added to an Agenda on a rolling basis after BSO and IBC Analyst pre-reviews are complete.

Notification to the Committee
Distribution of the Agenda to all members occurs approximately 2 weeks in advance of the convened meeting.   All new MPRs, amendments, incidents and other business requiring full committee action are placed on the Agenda for discussion.

Access to the MPR Materials
Committee members have access to all of the MPR materials through the electronic submission and review system.

Reviewer Assignments
Primary and Secondary Reviewers are assigned by the RPO Analyst to review the submission and all provided materials.  Efforts are made to match the primary reviewer’s expertise to the project’s subject matter. Reviewers are encouraged to contact the PI to resolve/clarify major concerns prior to the meeting. The reviewers summarize the proposed research or teaching activities for the full Committee at a convened meeting and answer questions during the discussion.  An approval memo or a request for further clarification will be sent to the principal investigator.

Designated Member Review
The regulations have flexibility to allow for a designated member review process.  A new MPR or amendment to add a new project to an existing MPR may be reviewed by a designated member of the IBC under one or more of the following conditions:

  • The proposed work is equivalent to work already approved under the existing registration, as determined by the IBC, and there are no substantive differences that would change the biosafety and or public health considerations for the proposed project.
  • The proposed work receives a preliminary category of BSL1.

Assigning Reviewers
The submission will be assigned to a designated member for review once the BSO and IBC Analyst pre-reviews are complete.  The Chair reserves the right to also provide the materials to each member of the Committee for review. If no additional clarifications or requests for a Full Committee review at a convened meeting are received, an approval will be signed at the discretion of the Chair.  An approval memo or a request for further clarification will be sent to the principal investigator.

Review Simultaneous with Initiation
The regulations allow for review simultaneous with initiation of the project if the experiments are BSL1 and fall under Section III-E of the NIH guidelines. In these instances, researchers will follow the designated review process listed above. 

Exemption Determinations
The regulations allow exemption from IBC review for experiments falling within Section III-F. Though these projects may be exempt from the Guidelines, they still need to be forwarded electronically to the IBC for a formal determination and review of other Federal, State, and local biosafety standards that may apply.  The Chair and Biosafety Officer will make the determination of exemption.

Section III-F.    Exempt Experiments

The following recombinant or synthetic nucleic acid molecules are exempt from the NIH Guidelines and registration with the Institutional Biosafety Committee is not required; however, other federal and state standards of biosafety may still apply to such research (for example, the Centers for Disease Control and Prevention (CDC)/NIH publication Biosafety in Microbiological and Biomedical Laboratories).

Section III-F-1.  Those synthetic nucleic acids that:  (1) can neither replicate nor generate nucleic acids that can replicate in any living cell (e.g., oligonucleotides or other synthetic nucleic acids that do not contain an origin of replication or contain elements known to interact with either DNA or RNA polymerase), and (2) are not designed to integrate into DNA, and (3) do not produce a toxin that is lethal for vertebrates at an LD50 of less than 100 nanograms per kilogram body weight.  If a synthetic nucleic acid is deliberately transferred into one or more human research participants and meets the criteria of Section III-C, it is not exempt under this Section.

Section III-F-2.  Those that are not in organisms, cells, or viruses and that have not been modified or manipulated (e.g., encapsulated into synthetic or natural vehicles) to render them capable of penetrating cellular membranes.

Section III-F-3.  Those that consist solely of the exact recombinant or synthetic nucleic acid sequence from a single source that exists contemporaneously in nature.

Section III-F-4.  Those that consist entirely of nucleic acids from a prokaryotic host, including its indigenous plasmids or viruses when propagated only in that host (or a closely related strain of the same species), or when transferred to another host by well-established physiological means.

Section III-F-5.  Those that consist entirely of nucleic acids from a eukaryotic host including its chloroplasts, mitochondria, or plasmids (but excluding viruses) when propagated only in that host (or a closely related strain of the same species).

Section III-F-6.  Those that consist entirely of DNA segments from different species that exchange DNA by known physiological processes, though one or more of the segments may be a synthetic equivalent.  A list of such exchangers will be prepared and periodically revised by the NIH Director with advice of the RAC after appropriate notice and opportunity for public comment (see Section IV-C-1-b-(1)-(c), Major Actions).  See Appendices A-I through A-VI, Exemptions under Section III-F-6--Sublists of Natural Exchangers, for a list of natural exchangers that are exempt from the NIH Guidelines.

Section III-F-7.  Those genomic DNA molecules that have acquired a transposable element, provided the transposable element does not contain any recombinant and/or synthetic DNA.

Section III-F-8.  Those that do not present a significant risk to health or the environment (see Section IV-C-1-b-(1)-(c), Major Actions), as determined by the NIH Director, with the advice of the RAC, and following appropriate notice and opportunity for public comment.  See Appendix C, Exemptions under Section III-F-8 for other classes of experiments which are exempt from the NIH Guidelines.

Administrative Review/Approval
IBC staff will review and approve study team member changes and continuing reviews.


Back to Top


2.2 IBC Review Determinations

The IBC shall review and have authority to approve, require modifications in (to secure approval), or disapprove all research and teaching activities covered by this policy, including exempt research activities.

This decision indicates that the initial review of a master protocol registration (MPR) at a convened meeting or via designated review has been approved without requiring either further (a) changes to the MPR or (b) submission of clarifications or additional documents.

This decision indicates approval is pending satisfactory resolution of conditions or clarifications that the IBC requires to approve the MPR. Under this scenario, for full review MPRs, further review by the IBC at a subsequent convened meeting is not necessary to secure final approval.

The designated review process is employed to review the response from the investigator. The IBC directs that the IBC chairperson (or other individual(s)) to review and determine on behalf of the IBC whether the changes, clarifications, and/or additional documents to be submitted by the investigator(s) are satisfactory.

If under the designated review of the response, the IBC chairperson (designated reviewer) is unable to approve the MPR because he/she cannot make the determinations required for approval, they can either refer the project to the IBC for further review and action at a convened meeting, or defer approval of the MPR and require that the investigator (a) make changes to the MPR, or (b) submit clarifications or additional documents prior to further review by the IBC chairperson (or designated reviewer(s)).

DEFERRED (tabled)
This action is taken under full Committee review any time the IBC cannot make one or more of the determinations required for approval but with major revisions may be found to be approvable. When deferring a project, the IBC, under its authority to require modifications in order for an investigator to secure approval, may require that the investigator (a) make changes to the MPR or (b) submit clarifications or additional documents.  The research may not proceed until the IBC reviews, at a subsequent convened meeting, the revised MPR and approves it.

This action is taken under full Committee review when the determinations required for approval of the research cannot be made, even with substantive clarifications or modifications to the MPR. If the IBC decides to withhold approval of a MPR, it will include in its written notification a statement of the reasons for its decision.

The above review determinations also apply to follow on submissions to an approved MPR including amendments and continuing reviews. 

All currently approved research is subject to modification or change in approval status, as deemed necessary by the IBC. The IBC has the authority to suspend or terminate research for not being conducted in accordance with IBC requirements or federal regulations; or if it has been associated with unexpected harm to personnel or the environment. The Investigator also has the option to place the research on administrative hold.

Administrative Hold
An administrative hold is a voluntary action by an investigator to temporarily or permanently stop some or all approved research activities. Administrative holds are not considered suspensions or terminations, and do not meet reporting requirements to the Office of Science Policy. Administrative holds must not be used to avoid reporting deficiencies or circumstances that otherwise require reporting to federal agencies. The Principal Investigator may place an administrative hold on research if; a complaint is received; an allegation of non-compliance is reported to the IBC; or a discovery by the investigator of new potential risk to personnel or the environment.  The Investigator must notify the IBC of the hold through an amendment.

During administrative hold, the research remains subject to continuing review and requirements for reporting non-compliance and incidents.

The IBC designee may make recommendations for additional education and/or compliance interventions for the Investigator and research personnel as the result of an administrative hold. At any point, the IBC Committee can suspend the research, which will result in required regulatory reporting.

A suspension of IBC approval is a directive of the convened IBC, Biosafety Officer or IBC designee either to stop temporarily some or all previously approved research activities, or to stop permanently some or all previously approved research activities. All suspensions are immediately reportable to federal agencies.

The Biosafety Officer has the authority to suspend previously approved research when required for the urgent protection of personnel and/or the environment and insufficient time exists for the convened IBC to review the issue. Any suspension of research by the above individuals is placed on the next available agenda of a meeting of the full IBC.  The convened IBC will review the circumstances that led to the suspension and will make the determination to uphold or overturn the suspension. The IBC will recommend corrective actions if the suspension is upheld.

During suspension, the research remains subject to continuing review and requirements for reporting non-compliance and incidents.

The IBC Chair, Biosafety Officer, or designee notifies the investigator of the suspension and the reason for the suspension.

A termination of IBC approval is a directive of the convened IBC or IBC designee to permanently stop all previously approved research activities. All terminations are reportable to federal agencies. MPR approval will not be terminated without first undergoing temporary suspension and completion of a review following the Noncompliance Policy and Procedures process.

Previously approved research may only be terminated by the convened IBC, including MPRs originally approved under designated procedures.

Terminated protocols are considered closed and no longer require continuing review.


Back to Top


2.3 Coordination with Other Compliance Committees/Divisions/Cores

Animal Use (IACUC)
Review by the IBC is independent of the review by the Institutional Animal Care and Use Committee (IACUC).  However, there is representation on both committees that communicate and coordinate regarding Biosafety issues in animal studies.  Initiation of the animal component of the study is contingent upon the completion of and approval of IACUC process.

Human Subjects (IRB)
Review by the IBC is independent of the review by the Institutional Review Board (IRB). 

Sponsored Project Administration (SPA)
SPA requires documentation of protocol approvals prior to release of funds.   IBC staff share protocol statuses with SPA for this purpose.

Institutional Review Entity (IRE) Subcommittee
The IRE is a subcommittee of the IBC.  Researchers who believe that they may be conducting DURC are required to submit a MPR to the IBC for review and initial determination.  The IBC and IRE work closely to ensure proper oversight of DURC.  See Section 3.5 for the organizational framework for oversight of DURC.  

UVM Core Facilities
An ancillary review will be sent to the director of each core facility when an MPR indicates their use.


Back to Top

2.4 Conducting IBC Business in the Event of a Pandemic or other Significant Emergency

IBC Meetings

Internal policies state that convened meetings are required for 1) initial review of Master Protocol Registrations (MPR) that propose the use of non-exempt biohazardous materials in a risk category greater than or equal to Biosafety Level 2 (BSL2); 2) any amendments that have the potential to increase Biosafety Level; 3) determinations of level of seriousness for noncompliance cases.  While optimal, there is no requirement to conduct the convened meeting in person.  Use of teleconferencing or audio/video conferencing is permissible.  If quorum cannot be achieved, convened meetings will be postponed until enough members can be present. 

Security of IBC remote meetings will be assured by using only University-approved videoconferencing software logging in only with UVM credentials.  Guest presence will be controlled by the meeting owner which, is typically a RPO staff person.  IBC videoconference meetings will not be recorded.  Quorum of members will assured by a count of those in attendance prior to opening the meeting and a second time after moving into open session prior to the protocol vote. 

Minutes of meetings will be captured following current methods for in-person meetings.  The manner of engagement of each member will be noted (e.g. in-person, telephone, video.)  Votes to go in or out of sessions, as well as to vote for specific registrations, will occur by the Chair asking for members who approve an order of business by asking “All approved say aye”, “All opposed say nay”, “All abstaining say aye”. Members participating through video conferencing can also use the chat feature to add comments to the discussion.   Members with conflicts will sign out of the meeting during the vote and IBC staff will invite them back into the meeting when the conflicting MPR discussion is complete.  Meeting guests will be invited during discussion of their registration and signed out once that discussion is completed.

MPR Review

New BSL2 MPRs or amendments to MPRs representing a potential for an increase in biosafety level must be reviewed in a convened meeting.  Convened meetings can proceed as described above. 

New BSL1 MPRs or amendments to existing MPRs which do not change the safety level can continue to be reviewed through the current designated review process.

MPR review documentation will be through the UVMClick-IRB electronic MPR submission software. 

Biosafety Officer Risk Assessments

The Biosafety Officer’s risk assessment will continue to be conducted when new work is proposed as long as the laboratory remains in operation.

Post Approval Monitoring

Post Approval Monitoring visits will be placed on hold until normal working conditions are in place.


If personnel refresher training expires during the emergency, personnel are allowed to continue their work as long as they have received previous training and have demonstrated proficiency.  There will be no consequences; however, once working conditions have been restored, personnel must complete refresher training in accordance with the IBC policy. 

Pause in Research Activities

If laboratory activities are required to be placed on pause secondary to institution-wide policy to address a public health situation, the IBC does not require notification in the pause of work. 


3. Master Protocol Registration (MPR) Submission

Researchers may now submit one master protocol registration (MPR) to cover multiple projects with similar biosafety levels.  Additionally, teaching laboratories that utilize biohazardous materials must submit a MPR describing the work and safe handling procedures being conducted in the teaching laboratory.  Adopting this model will reduce regulatory burden.  Researchers/professors will combine multiple teaching, or internally- and externally-funded projects under one MPR.  Laboratory activities requiring BSL-1 and BSL-2 work practices may be combined. Projects necessitating BSL-3 work practices must be registered under their own separate MPR as depicted in the image below.


Since the MPRs are grouped together based upon biosafety levels (BSL-1/2 or BSL3), it is important that this level is established early in the review process for a new project.  The following tools can help researchers make an initial determination of the appropriate risk group, containment level and work practices.  The Biosafety Officer or his delegate, after collecting the details necessary at a laboratory site visit, will bring his/her recommendation to the full Committee who will make the final risk group and containment level determination. 

The NIH/CDC BMBL 5th edition publication will help get you started in making a risk assessment. 

The American Biological Society Association maintains an excellent reference for risk groups.


Back to Top


3.1 Initial PI Risk Assessment

It is the responsibility of all PIs to provide an initial assessment of the risk factors and risk levels involved in their proposed activities.  In many instances, the PI has significant experience working with similar biological agents or recombinant DNA and is in the best position to estimate the appropriate biosafety level (BSL-1, BSL-2 or BSL-3) for the laboratory. 

A thorough risk assessment involves three stages:  a PI risk assessment, a Biosafety Officer risk assessment, and confirmation by the IBC.

The following guidance on risk assessment is provided to assist PI’s in conducting an accurate and effective risk assessment. The steps listed below are modified excerpts from the Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition publication:

Step 1: Identify agent hazards and perform an initial assessment of risk. Consider the principle hazardous characteristics of the agent, which include its capability to infect and cause disease in a susceptible human host, severity of disease, and the availability of preventive measures and effective treatments.

Step 2: Identify laboratory procedure hazards. The principle laboratory procedure hazards are agent concentration, suspension volume, equipment and procedures that generate small particle aerosols and larger airborne particles (droplets), and use of sharps. Procedures involving animals can present a number of hazards such as bites and scratches, exposure to zoonotic agents, and the handling of experimentally generated infectious aerosols.

Step 3: Make an [initial] determination of the appropriate biosafety level and select additional precautions indicated by the risk assessment. Note: Biosafety Officer and the IBC will make the final biosafety level determination.

Step 4: Evaluate the proficiencies of staff regarding safe practices and the integrity of safety equipment.

In conducting a risk assessment, the PI should ensure that laboratory workers have acquired the technical proficiency in the use of microbiological practices and safety equipment required for the safe handling of the agent, and have developed good habits that sustain excellence in the performance of those practices.


Back to Top


3.2 Biosafety Officer (BSO) Risk Assessment

Risk assessments conducted by the Biosafety Officer assist the PI in determining the appropriateness of the proposed facilities, procedures, practices, whether there is adequate training, and expertise of personnel involved in the requested use of these materials and the recommended risk and containment levels.

Note:  The UVM IBC reviews applicable protocols involving human subjects who are being treated at The University of Vermont Medical Center (UVMMC).  The UVM Biosafety Officer works with specific UVMMC service lines (see gene therapy) to ensure that an appropriate risk assessment is conducted.  


The primary focus of risk assessment is to prevent or reduce the risk of laboratory-associated infections. Agents are classified into four Risk Groups according to their relative pathogenicity for healthy adult humans as follows:

  • Risk Group 1 (RG-1) agents are not associated with disease in healthy adult humans.
  • Risk Group 2 (RG-2) agents are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available.
  • Risk Group 3 (RG-3) agents are associated with serious or lethal human disease for which preventive or therapeutic interventions may be available.
  • Risk Group 4 (RG-4) agents are likely to cause serious or lethal human disease for which preventive or therapeutic interventions are not usually available.

Risk Factors

The following factors will be considered when conducting a risk assessment and determining the level of containment:

  • Pathogenicity of the biohazardous material(s) - Consideration should include disease incidence and severity.
  • Route of transmission (e.g., parenteral, airborne, by ingestion) - When planning to work with a relatively uncharacterized agent with an uncertain mode of transmission, the potential for aerosol transmission should be strongly considered.
  • Agent stability - Should include a consideration of factors such as desiccation, exposure to sunlight or ultraviolet light, or exposure to chemical disinfectants.
  • Infectious dose of the agent and communicability - Consideration should include the range from the healthiest immunized worker to the worker with lesser resistance.
  • Concentration - Include consideration of the milieu containing the organism (e.g., solid tissue, viscous blood or sputum, liquid medium) and the activity planned.
  • Volume - >10 liters is considered large scale and is subject to further review and higher containment level.
  • Origin of the biohazardous material(s) - Consideration should include factors such as geographic location, host, and nature of the source.
  • Availability of data from animal studies - This information may be useful in the risk assessment process in the absence of human data.
  • Established availability of immunization/vaccine or treatment - The unavailability of immunization/vaccine or treatment may impact the risk involved in the use of biohazardous material(s).
  • Gene product effects, such as toxicity, physiological activity, and allergenicity.

Biosafety Level (Biological and Physical Containment Level)

The final risk assessment determination (RG-1 to RG-4) is used to set the appropriate biosafety level (BSL-1 to BSL-4) for the biohazardous material(s). The biosafety level describes the degree of physical containment and biosafety practices required to confine these materials and to reduce the potential for exposure of laboratory workers, persons outside the laboratory, and the environment. The UVM Biosafety Officer and Biosafety Coordinator reserve the authority to require enhanced practices to afford a higher level of protection to personnel as necessary.

The following is a general description of the biosafety levels as described in the Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th edition:

  • Biosafety Level 1 (BSL-1) is suitable for work involving well-characterized agents not known to consistently cause disease in immunocompetent adult humans, and present minimal potential hazard to laboratory personnel and the environment. BSL-1 laboratories are not necessarily separated from the general traffic patterns in the building. Work is typically conducted on open bench tops using standard microbiological practices. Special containment equipment or facility design is not required, but may be used as determined by appropriate risk assessment. Laboratory personnel must have specific training in the procedures conducted in the laboratory and must be supervised by a scientist with training in microbiology or a related science.
  • Biosafety Level 2 (BSL-2) builds upon BSL-1. BSL-2 is suitable for work involving agents that pose moderate hazards to personnel and the environment. It differs from BSL-1 in that 1) laboratory personnel have specific training in handling pathogenic agents and are supervised by scientists competent in handling infectious agents and associated procedures; 2) access to the laboratory is restricted when work is being conducted; and 3) all procedures in which infectious aerosols or splashes may be created are conducted in a biosafety cabinet (BSC) or other physical containment equipment.
  • Biosafety Level 3 (BSL-3) is applicable to clinical, diagnostic, teaching, research, or production facilities where work is performed with indigenous or exotic agents that may cause serious or potentially lethal disease through inhalation route exposure. Laboratory personnel must receive specific training in handling pathogenic and potentially lethal agents, and must be supervised by scientists competent in handling infectious agents and associated procedures.  All procedures involving the manipulation of infectious materials must be conducted within BSCs, other physical containment devices, or by personnel wearing appropriate personal protective equipment.  A BSL-3 laboratory has special engineering and design features.

NOTE: There are also biosafety levels for work with infectious agents in vertebrate animals. For a complete description of the animal biosafety levels, consult the BMBL. http://www.cdc.gov/biosafety/publications/bmbl5/index.htm

The biosafety level may be equivalent to the Risk Group classification of the agent or it may be raised or lowered based on the results of the risk assessment. If you have any questions regarding the risk assessment or appropriate containment level, you may consult with the IBC. The IBC makes the final determination of the appropriate biosafety level.


Back to Top


3.3 Research Including Recombinant DNA or Synthetic Nucleic Acid Molecules

The Biosafety Policy and Recombinant DNA Policy Program manages and evaluates the current biosafety policies for research at institutions that receive NIH support.  The program administers the NIH Guidelines.

In the context of the NIH Guidelines, recombinant and synthetic nucleic acids are defined as:

(i) molecules that a) are constructed by joining nucleic acid molecules and b) that can replicate in a living cell, i.e., recombinant nucleic acids;
(ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e., synthetic nucleic acids, or
(iii) molecules that result from the replication of those described in (i) or (ii) above.

As a condition for NIH funding of recombinant or synthetic nucleic acid molecule research, institutions shall ensure that such research conducted at or sponsored by the institution, irrespective of the source of funding, shall comply with the NIH Guidelines.

Section III of the NIH Guidelines details the type of experiments covered by the Guidelines and the level of reviewed required.


Back to Top


3.4 Research Including Animals

MPRs which involve the exposure of animals to recombinant and/or synthetic nucleic acid molecules, infectious agents or biotoxins require review by the IBC and the Institutional Animal Care and Use Committee (IACUC) committees. This includes the generation of new strains of genetically-modified animals using transgenic, homologous recombination or genome editing approaches. 

The office allows simultaneous reviews with the IBC and IACUC committees.  However, to protect animals, the IACUC approval will not be released until IBC has approved appropriate containment conditions required for the animal experiments and animal housing. 

Both the IBC and the IACUC will review incident reports and changes in projects submitted during the course of the research.


Back to Top


3.5 Research Including Infectious Agents

Infectious agents include any biological agents and biologically derived materials that present a risk or potential risk to the health of humans or animals, either directly through infection or indirectly through damage to the environment.

Categories of Potentially Infectious Materials

  • Human, animal, and plant pathogens (bacteria, parasites, fungi, viruses, prions).
  • All human blood, blood products, tissues, and certain body fluids when used in conjunction with infectious agents or recombinant or synthetic nucleic acid molecules.
  • Cultured cells and potentially infectious agents these cells may contain.
  • Clinical specimens.
  • Infected animal and animal tissues.

Centers for Disease Control and Prevention (CDC)

The CDC has set forth an advisory document, the PDF iconBiosafety in Microbiological and Biomedical Laboratories (BMBL) - (PDF), regarding best practices for the safe conduct of work in biomedical and clinical laboratories from a biosafety perspective.  The IBC uses this document to conduct review of these types of projects. To address the requirements of the BMBL, the principal investigator must:

  • Limit or restrict access to the laboratory when work with infectious agents is in progress. The PI must include a determination of who may be at increased risk and appropriately limit or deny access.
  • Establish policies and procedures to limit access to those individuals who have been advised of the potential hazards and meet specific entry requirements (e.g., immunization).
  • Ensure that laboratory personnel are offered, at no cost, appropriate immunizations or tests for the infectious agents handled or potentially present in the laboratory (e.g., hepatitis B vaccine, tuberculosis skin testing).
  • Select and provide appropriate personal protective equipment required for work with biohazardous materials.
  • Ensure that laboratory and support personnel receive appropriate training on the potential hazards associated with the work involved, the necessary precautions to prevent exposures, the exposure evaluation procedures, and that personnel receive annual updates or additional training as necessary for procedural or policy changes.
  • Develop standard operating procedures incorporating biosafety procedures or a biosafety manual prepared specifically for the laboratory, advise personnel of special hazards, and require them to read and follow instructions on practices and procedures.

Local Requirement for Standard Operating Procedures

For projects including infectious agents and certain viral vectors, a standard operating procedure or an applicable Biohazardous Agent Reference Document (BARD) is required as part of the MPR submission.  A standard operating procedure template may be found here. BARDs were developed by the IBC to assist researchers in development of these procedures.  Researcher may use the BARDs as written or the BARDs may be edited as applicable.  The BARD templates are found at


Back to Top

3.5.1 Research including Adeno-Associated Virus

Adeno-associated virus (AAV) and recombinant adeno-associated virus (rAAV) are commonly used for gene expression with fewer associated biosafety concerns when compared to viral vectors that are persistent and able to integrate into the genome. The IBC will apply the following criteria for determining the appropriate biosafety containment and handling of AAV:

  • BSL-1 Transgene does not express an oncogene or toxin, viruses generated without helper virus, acceptable verification that helper virus is not present, or propagation in insect cell lines
  • BSL-2 Transgene that expresses an oncogene or toxin, viruses that are propagated in human cell lines without further purification before use, known presence of helper virus, or lack of acceptable verification of purification

Registrations including rAAV must attach the Adeno-Associated Viral Vector (AAV) BARD with completed Summary of Biosafety Level Requirements for AAV Use (located on the last page of the BARD document).

Back to Top

3.6 Research Including Biotoxins

Biological toxins can include metabolites of living organisms, degradation products of dead organisms, and materials rendered toxic by the metabolic activity of microorganisms.  Some toxins can also be produced by bacterial or fungal fermentation, by the use of recombinant and synthetic nucleic acid molecule technology, or by chemical syntheses of low molecular weight toxins.  Protocols utilizing biotoxins must be reviewed by the IBC prior to use. 

For more information and a list of biotoxins refer to https://emergency.cdc.gov/agent/agentlist.asp.


Back to Top


3.7 Research Including Select Agents and Toxins

Select agent/toxins are under the purview of the Federal Select Agent Program under the Centers for Disease Control and Prevention.  The Program oversees the possession, use and transfer of biological select agents and toxins, which have the potential to pose a severe threat to public, animal or plant health or to animal or plant products.

The Program greatly enhances the nation’s oversight of the safety and security of select agents by:

  • Developing, implementing, and enforcing the Select Agent Regulations
  • Maintaining a national database
  • Inspecting entities that possess, use, or transfer select agents
  • Ensuring that all individuals who work with these agents undergo a security risk assessment performed by the Federal Bureau of Investigation/Criminal Justice Information Service
  • Providing guidance to regulated entities on achieving compliance to the regulations through the development of guidance documents, conducting workshops and webinars
  • Investigation of any incidents in which non-compliance may have occurred

For a list of select agents please go to https://www.selectagents.gov/SelectAgentsandToxinsList.html.  If you intend to use a select agent, please contact the IBC for further information prior to obtaining the agent.


Back to Top


3.8 Research Including Human Subjects

IBC will interact with the Institutional Review Board (IRB) in the review of research that includes human research participants; including, but not limited to, Recombinant DNA/Human Gene Transfer (HGT) and research with biologically derived toxins or infectious agents.  In general, the IBC advises the IRB on risk assessment and biosafety issues according to the NIH guidelines. 

Process to Obtain Approval

Food and Drug Administration Approval
FDA approval is required prior to any institutional review. Feasibility approvals are required from the following hospital services, regardless of sponsorship.

• Investigational Drug Pharmacy
• Environmental Health and Safety Department
• Infectious Disease
• Infection Prevention

Each of these services lines will need to see the following materials:

• Clinical Trial Protocol
• Investigational Drug Brochure
• Standard Operating Procedures for Drug Preparation
• Standard Operating Procedures for Transport of the Drug
• Standard Operating Procedures for Handling Drug by Clinical Staff

IBC Review
Once all service lines have agreed that the project can be conducted, the MPR can be submitted to the IBC for review.  Data entry of the project into Click to include the following uploads:

• Hospital service line approvals;
• Clinical Trial Protocol;
• Investigational Drug Brochure;
• Informed consent draft.

IRB Review
Once the IBC has provided a provisionary approval, the human subject protocol can be submitted for review by the Institutional Review Board.

Note:  All previous requirements to obtain approval from the Recombinant DNA Advisory Committee and to register with NIH no longer exist as of August 2018.


Back to Top


3.9 Projects Involving Plants (NIH Appendix P)

Projects involving plants require review by the IBC committee.  Consultants may be called upon to address these types of protocols.


Back to Top


3.10 Dual Use Research of Concern

Despite its value and benefits, certain types of research conducted for legitimate purposes can be utilized for both benevolent and harmful purposes.  Such research is called “dual use research.”  Dual use research of concern (DURC) is life sciences research that, based on current understanding, can be reasonably anticipated to provide knowledge, information, products, or technologies that could be directly misapplied to pose a significant threat to public health and safety, agricultural crops and other plants, animals, the environment, material or national security. 

The PDF icon“U.S. Government (USG) Policy for Oversight of Life Sciences Dual Use Research of Concern” (PDF) articulates the practices and procedures required to ensure that dual use research of concern is identified at the institutional level and risk mitigation measures are implemented as necessary. 

Designation of an Institutional Contact for DURC (ICDUR)
The Executive Director for Research Administration is designated as the institution’s ICDUR.  The ICDUR serves as the internal resource for issues regarding compliance with and implementation of the requirements for the oversight of research that falls within the scope and/or meets the definition of DURC. If questions arise regarding compliance, implementation of this Policy or when guidance is needed about identifying DURC or developing risk mitigation plans, the ICDUR serves as the liaison (as necessary) between UVM and the relevant program officers at the Federal funding agencies, or for non-Federally funded research, between UVM and NIH (or the appropriate Federal funding agency to which NIH refers the institution). 

Initial Identification and Review of Dual Use Research of Concern
The USG has limited the scope to a well-defined subset of life sciences research that involves 15 agents and toxins and seven categories of experiments.

Agents and Toxins

Avian influenza virus (highly pathogenic)

Marburg virus

Bacillus anthracis

Reconstructed 1918 Influenza virus

Botulinum neurotoxin

Rinderpest virus

Burkholderia mallei

Toxin-producing strains of Clostridium botulinum

Burkholderia pseudomallei

Variola major virus

Ebola virus

Variola minor virus

Foot-and-mouth disease virus

Yersinia pestis

Francisella tularensis


Categories of Experimental Effects

  • Enhances the harmful consequences of the agent or toxin
  • Disrupts immunity or the effectiveness of an immunization against the agent or toxin without clinical and/or agricultural justification
  • Confers to the agent or toxin resistance to clinically and/or agriculturally useful prophylactic or therapeutic interventions against that agent or toxin or facilitates their ability to evade detection methodologies
  • Increases the stability, transmissibility, or the ability to disseminate the agent or toxin
  • Alters the host range or tropism of the agent or toxin
  • Enhances the susceptibility of a host population to the agent or toxin
  • Generates or reconstitutes an eradicated or extinct agent or toxin listed above.

How Dual Use Research of Concern is Confirmed
All projects involving biohazardous materials are submitted through the electronic submission system.  The electronic form includes specific questions to help assess whether a project may be dual use research.  When research is identified by a PI as utilizing one of the listed agents or toxins, the project will be initially reviewed by the IBC Chair and the Biosafety Officer who will make the following determinations:

  • Verification that research utilizes one or more of the agents or toxins listed;
  • Determination of whether the research produces, aims to produce, or is reasonably anticipated to produce one or more of the effects listed;
  • Assessment of the dual use risks and the benefits of the research;
  • Review proposed risk mitigation plan for DURC, as necessary.

If determined by the initial review that the project is not DURC, then the project will continue through the regular review process.  If it is determined to be DURC, the project will be referred to the Institutional Review Entity (IRE).  See flow chart below.

Institutional Review Entity (IRE) Review
The full IRE consists of the UVM Biosafety Officer, the Chair of the IBC, the Director of The Research Protections Office, the Assistant Director for Health & Safety, the Executive Director for Research Administration, a community member, representatives of the scientific community, and an individual from the State Department of Health.  When appropriate, representatives from Police Services, University Communications, or a representative of the Office of the General Counsel will be consulted as needed.   The IRE functions as follows:

  • With sufficient empowerment by the institution to ensure compliance with the institution’s dual use research policies.
  • Maintain sufficient breadth of expertise to assess the dual use potential of the range of relevant life sciences research conducted at a given research facility.
  • Maintain knowledge of dual use issues, concerns, and related institutional and Federal policies and understand risk assessment and risk management considerations. The review entity should be aware that a variety of risk mitigation measures are available and that designating research as DURC does not necessarily mean that the research should not be conducted or communicated.
  • Make its procedures for reviewing life sciences research for dual use potential accessible to the public. The posted policies of the institution should include an overview of the institution’s procedures or review process, but should not include details of particular cases or the minutes of the DURC review entity’s proceedings.
  • On a case by case basis, recuse any member of an institutional review entity who is involved in the research project in question or has a direct financial interest, except to provide specific information requested by the review entity.
  • Engage in an ongoing dialogue with the PI of the research in question when developing appropriate risk mitigation plans.
  • With the administrative infrastructure provided by the RPO, maintain records of institutional DURC reviews and completed risk mitigation plans for three years.

Each research initiative that is categorized as DURC is different and requires unique consideration, dependent on the information, materials, or technologies that may result from the research. Therefore, it is not possible to develop a single review process that can be used for all cases. The IRE performs its reviews based on the National Science Advisory Board for Biosecurity (NSABB) guidance.

Dual Use

Minutes and Communication
The IRE committee maintains minutes of its deliberations and communicates its protocol review and risk mitigation plan recommendations in writing to the full IBC.

Appealing a Decision
Appeals may be made to the Vice President for Research through the ICDUR. 

Post DURC Approval Requirements

Responsibilities of the Institution

  • Within 30 calendar days of the institutional review of the research for DURC potential, notification of the Federal funding agency of any research that falls within the scope, including whether it meets or does not meet the definition of DURC. For non-Federally funded research, notification may be made to NIH (who may in turn notify the appropriate Federal funding agency, based upon the nature of the research); and
  • Within 90 calendar days from the time that the institution determined the research to be DURC, provision of a copy of the risk mitigation plan to the funding agency for review – or for non-Federally funded research, provision of the plan to NIH for review (or referral to the appropriate funding agency).
  • The ICDUR will provide all formal assurances to NIH and other Federal funding agencies about its DURC activity and compliance with the relevant policies in annual reports.
  • The IBC follows its noncompliance reporting process ensuring that measures are undertaken by the institution to prevent recurrences of similar noncompliance.  The noncompliance will be reported within 30 calendar days to the Federal funding agency or, for non-Federally funded research, to NIH (which will receive for administrative purposes on behalf of all of the institution’s Federal funders) and to the UVM Institutional Official.

Responsibilities of Principal Investigators

  • Identify his or her research involving one or more of the DURC agents or toxins and follow the appropriate IBC and IRE review process for review of DURC potential.
  • Work with the IRE to develop risk mitigation measures where appropriate.
  • Conduct DURC in accordance with the provisions of the risk mitigation plan.
  • Be knowledgeable about and comply with all institutional and Federal policies and requirements for oversight of DURC.
  • Ensure that laboratory personnel conducting DURC (i.e., those under the supervision of laboratory leadership, including graduate students, postdoctoral fellows, research technicians, laboratory staff, and visiting scientists) have received education and training on DURC.
  • Communicate DURC in a responsible manner. Communication of research and research findings is an essential activity for all researchers, and occurs throughout the research process, not simply at the point of publication. When researchers are planning to communicate DURC, it is their duty to ensure that it is done in a responsible manner, and in compliance with any risk mitigation plan approved by the IRE.

Education and Training
The IBC provides education and training on DURC for individuals conducting life sciences research that falls within the scope of this Policy.  At a minimum, all DURC researchers will be required to complete the basic and DURC-specific module in CITI.  Additional training is required consistent with the approved protocol and standard operating procedures. Links to educational materials developed by the Office of Biotechnology Activities is located on our IBC website.

The IBC maintains records of personnel training on dual use research for three years. As necessary, the IBC assists the PIs of life sciences research when questions arise about whether their research may require further review or oversight.

Risk Mitigation Plan
After a risk mitigation plan is developed by the PI and approved by the IRE, the research must be conducted in accordance with that plan and must be periodically reviewed by the institution to determine if additional modifications to the risk mitigation plan are appropriate.


Back to Top


4. Subsequent Submission Requirements

Once a Master Protocol Registration has been approved, the principal investigator has the responsibility of informing the IBC of changes in PI, key personnel, reporting incidents, submitting an annual continuing review, and closing the registration when the master protocol registration is no longer needed.  Submissions are made to the IBC through the UVMClick system using the Amendment, Incident, Continuing Review, and Closure Request activities.


Back to Top


4.1 Amendment to Approved Master Protocol Registration

Principal investigators revising a currently approved MPR must complete an Amendment smart form in UVMClick, revise appropriate smart form pages, and submit to the IBC for approval. Changes involving modification of biological agents, significant procedure changes (including change of the responsible principal investigator), changes to personnel, or changes that increase the risk of the project and/or the biosafety level must be approved by the IBC prior to implementing the changes.

Once approved, the Committee will return a signed approval memo back to the principal investigator.

NOTE: If the amendment involves vertebrate animals or human subjects, additional review by other committees may be required prior to implementation.


Back to Top


4.2 Addition of a New Funded Project to an Approved Master Protocol Registration

The IBC MPR is not grant specific and there is no need to submit multiple registrations for different funding sources. When a new grant is funded, an amendment to the existing MPR should be made to add the new source of funding and any new work involving biohazardous materials resulting from the approved grant. The amendment smart form should describe any new materials and any changes in research activities involving those materials. New or revised SOPs or BARDs must be submitted for review and approval as well.


Back to Top


4.3 Continuing Review of Master Protocol Registration

Annually, UVMClick-IBC will send a continuing review reminder to the principal investigator and his/her delegated proxy three months before the approval of an MPR is due to expire. Additional reminders will be sent at two months and one month prior to expiration.  The principal investigator or proxy must log into the system and complete a continuing review smart form and submit to the Committee for review.

Once approved, the Committee will return a signed approval memo to the principal investigator.


Back to Top


4.4 Laboratory Accidents/Exposures/Spills (incidents)

All biological exposures (i.e., life-threatening events), illness, or significant accident leading to, or potentially leading to illness or that is environmentally dangerous to humans and/or animals must be reported to the IBC as soon as possible.
The Chair and Biosafety Officer reviews all incident reports whether there has been an exposure or a near miss.  All incidents will be reported to the IBC at a regularly convened meeting at which time the IBC may require additional safeguards or changes in procedures.

If applicable, additional research committee meetings will be convened to discuss the incident and all biosafety procedures associated with the event.  In some instances the Chair of the IBC may suspend all relevant biohazardous materials use by the PI pending clearance from the IBC and consultation with medical specialists.  Noncompliance issues will be reviewed following the Noncompliance Policy Procedures. 

The IBC will share information about the reported event as applicable with the Office of Animal Care Management, the Institutional Animal Care and Use Committee, and the Institutional Review Board. 

The NIH Guidelines specifically require the reporting of significant problems, violations of the NIH Guidelines, or any significant research-related accident or illness by the Institution, the Institutional Biosafety Committee, or the Principal Investigator.

The Institutional Official will report in writing, incidents that involve recombinant and synthetic nucleic acid molecules to:

Office of Biotechnology Activities
National Institutes of Health
6705 Rockledge Drive, Suite 750, MSC 7985
Bethesda, MD 20892-7985 (20817 for non-USPS mail)
Phone: 301-496-9838
Fax: 301-496-9839

Following recommendations from the IBC, the Institutional Official will inform external agencies such as the CDC, local public health department, State agencies, and funding sources about the incident and corrective actions.


Back to Top


4.5 Closing a Master Protocol Registration

Principal investigators have the responsibility to inform IBC when they wish to close a Master Protocol Registration.

Notification must be done by completing a Closure Request activity in UVMClick. This provides an opportunity for the researcher to update the Committee with activities and describe the disposition of any remaining biohazardous materials. The closure request will be reviewed by the IBC and the researcher will be sent an official closure letter once the closure has been reviewed.


Back to Top


5. Investigator Responsibilities

Investigators are responsible for complying with the IBC Policies and Procedures and any additional reporting requirements specified either by the sponsor or the regulating body. For example, any project that includes animals must be in compliance with the University’s Institutional Animal Care and Use Committee.

In addition, the principal investigator’s primary responsibilities include, but are not limited to the following:

1.  Delegation of Responsibilities

PIs must personally perform or delegate to qualified co-investigators or research staff all of the necessary tasks to carry out their studies.  Even when specific tasks are delegated, the PI remains ultimately responsible for proper conduct of the study and fulfillment of all associated obligations.

  • Proxies are staff who are assigned by the PI to create, edit, and submit protocol materials on their behalf through the electronic protocol submission software.  Proxies have the same control as the PI. 

2.  Proper Training and Oversight of the Research Team

The principal investigator is responsible for ensuring that the research team has appropriate training prior to and during the conduct of the study by:

  • Reviewing with all laboratory staff the master protocol registration documents that describe the potential biohazards and the precautions to be taken (e.g., hazards and risks, immunizations, personal protective equipment required, decontamination, storage and disposal, spill procedures). Instructing staff in aseptic techniques and in the biology of the organisms used in the experiments so that the potential biohazards can be understood and appreciated.
  • Faculty members, principal investigators and others responsible for directly, or indirectly, supervising labs will support and encourage a culture of safety and the use of best practices in the master protocol registration documents and procedures. This includes communicating safety and health as a core value, understanding the risks and requirements associated with the laboratories they oversee, assuring that appropriate precautions are taken against hazards and unsafe practices, that proper personal protective equipment is made available to all personnel, that workplace equipment and machinery is routinely maintained, that required medical surveillance of impacted employees is conducted, that regular safety inspections are performed and documented, and that students and employees receive job and hazard-specific safety training. (NOTE: This excerpt is taken from the UVM Laboratory Health and Safety Policy)
  • Required web-based: UVM has subscribed to the web-based training program, Collaborative Institutional Training Initiative (CITI). Personnel must complete the BSL-2 Basic Course in CITI.  Other required trainings as applicable to your master protocol registration, include Animal Biosafety, Nanotechnology, Select Agents and DURC. Web-based training is required and must be completed every three years. Reminder letters will be sent to personnel as their training expiration date nears. Reference the CITI Program Training page for additional information about required training and to check training completions.   If working in BSL3 level containment, appropriate training must be sought by contacting the Biosafety Officer. (NOTE: The IBC Committee will not approve key personnel until this requirement has been met.)
  • Instructing and training laboratory staff in the practices and techniques required to ensure safety and the procedures for dealing with accidents.
  • Informing laboratory staff of the reasons and provisions for any precautionary medical practices advised or requested.
  • Supervising the safety performance of the laboratory staff to ensure that the required safety practices and techniques are employed.
  • Investigating and reporting any significant problems pertaining to the operating and implementation of containment practices and procedures in writing to the IBC, NIH/OSP (as required), and/or other appropriate regulatory authorities.
  • Correcting work errors and conditions that may result in the release of these materials.
  • Ensuring the integrity of the biological and physical containment (biosafety level).

3. Adherence to Approved Projects

It is the principal investigator’s responsibility to conduct research in accordance with an IBC approved master protocol registration and ensure adherence at all times by the research team.  This includes making sure that amendments and other follow-on submissions are submitted for IBC review in a timely fashion, and then once approved, any changes are implemented by the research team.

Follow-on submissions include:

  • Continuing Review reports
  • Adverse events or incident reports
  • Amendments regular or Amendments to add new grant funded projects
  • Changes to research team
  • Premature closure/suspension of activities
  • Final study closure.

4. Access to Research Records

The investigator must provide direct access to all research records to the IBC staff. Dependent upon the project sponsorship there may be others with access needs, such as regulatory authorities.

5. Retention of Research Records

The regulatory mandated duration for records retention varies depending on which regulations apply to the research in question. UVM investigators need to ensure that their plan for record retention complies with the federal regulations as well as UVM Records Retention policy (PDF).

  • *IBC Records means all records of communications with the IBC and all approval documents.
  • **Research Records refers to documentation of all observations and other data pertinent to the investigation.

*Captured by the IBC within the electronic submission software.

**PI’s responsibility to ensure retention requirements are met.


Back to Top


5.1 Study Team Member Responsibilities

Study team members are individuals carrying out research or teaching activities with biohazardous materials or an individual overseeing activities with biohazardous materials in an academic setting. Team members are responsible for:

  • Conducting activities in a safe manner and following laboratory procedures.
  • Reporting incidents to their supervisor/PI and/or the IBC.
  • Reviewing and understanding the Master Protocol Registration and its scope and safety requirements.
  • Completing applicable safety and laboratory specific training.
  • Acting as proxies on the PI’s behalf.


Back to Top


6. Conflict of Interest

As an academic research institution, we must continually dedicate ourselves to the integrity of the research enterprise.

The IBC leadership, staff and affiliated IBC members are required to disclose significant financial interests (SFI) in accordance with University of Vermont Financial Conflict of Interest in Sponsored Research policy.

Selection of specific protocols for review by members is determined by the Committee's administrative staff and/or Chair. If an IBC member has a conflicting interest in a protocol (including, but not limited to being a principal investigator, a co-investigator, or a consultant on that protocol), that member may only provide information as requested by the IBC and will not be assigned to officially review nor vote on that protocol.

Investigators are required to certify or disclose whether or not they hold and Significant Financial Conflict Interest and complete training every 4 years through the CITI Program.  More information regarding policy and procedures can be found at https://www.uvm.edu/ovpr/research-integrity-financial-conflict-interest-sponsored-research.


Back to Top


7. Post Approval Monitoring

In order to assist the UVM research community in adopting best laboratory Biosafety practices that help ensure a safe laboratory environment, the UVM Institutional Biosafety Committee has adopted the practice of regularly assessing laboratories associated with an active IBC protocol.  Assessments are an opportunity for laboratory personnel to receive guidance on prudent laboratory/Biosafety practices and procedures, ask questions and voice concerns. This process is in addition to regular risk assessments conducted by the UVM Biosafety Officer in support of new protocols and amendments to existing protocols.

Assessment Frequency
Assessment frequency will depend upon the level of risk associated with the laboratory work and the principal investigators history of compliance/non-compliance with IBC policies. In the absence of any IBC related violations, the UVM IBC will adhere to the following assessment schedule:

This schedule includes teaching laboratories.

BSL-1 laboratories – every 3 years
BSL-2 laboratories – every 2 years
BSL-3 laboratories – annually

Post Approval


Back to Top


8. Procedures for Managing Noncompliance

It is the responsibility of the Institutional Biosafety Committee (IBC) to address noncompliance with University policies and procedures, the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, and the Biosafety in Microbiological and Biomedical Laboratories (BMBL) Manual for research which uses biohazardous materials within the institution.  To exercise this authority the IBC is empowered to inspect laboratories, procedure areas, animal housing areas, and to sequester research or training records. The IBC may receive reports via external complaints, internal complaints, Incident Reports, random and directed site visits with Biosafety Risk Assessments, and investigator or laboratory worker self-reporting. The IBC encourages faculty, staff and/or students to report instances of noncompliance.

This document describes the procedures for handling these matters.  This policy is not all encompassing, and the IBC reserves the right to use its discretion in individual cases. 


Noncompliance is defined as the conduct of research in a manner that deviates from the approved protocol or disregards or violates federal regulations and/or institutional policies. Noncompliance may result from intended or inadvertent actions or omissions by study personnel, and can range from relatively minor or technical deviations to serious deviations that threaten the safety of personnel or the environment. 

Serious Noncompliance is defined as noncompliance that, in the judgement of the IBC, potentially increases the risk of harm to personnel or the environment.

Continuing Noncompliance is defined as a pattern of noncompliance (recurring or ongoing) that, in the judgement of the IBC, may indicate an underlying deficiency in knowledge of the regulations or IBC requirements or an unwillingness or inability to comply with these regulations/requirements.

General Noncompliance Review Procedures

The investigation of potential noncompliance begins when the IBC becomes aware of potential noncompliance. This may include an allegation (unproved assertion) of noncompliance, a self-disclosure of noncompliance, or any other indication that noncompliance may have occurred.  The process for the review of potential noncompliance involves initial administrative review, followed by an inquiry/fact finding process if indicated.  Once complete, the IBC makes a determination as to whether the noncompliance is serious, continuing, or neither. The IBC determination will be documented in a summary report that contains a corrective action plan in cases of serious or continuing noncompliance. This process is detailed below, however at any point in the review process, the IBC Chair or Associate Chair, University Biosafety Officer, University Veterinarian, RPO Director or Assistant Directors, or another Institutional Representative designee may at their discretion:

  • Recommend intervention for the safety of personnel or the environment
  • Recommend the suspension of research activities
  • Inform, involve, and/or provide salient documents to the PI, members of the research team, the Department Chair, Dean, legal counsel, or Institutional Officials, as appropriate
  • Initiate reporting per federal regulations
  • Initiate a monitoring visit
  • Recommend immediate corrective actions

Process of Noncompliance Review and Determination

Initial Review of Allegation or Indication of Noncompliance: When there is an allegation or indication of noncompliance, the first step is an administrative review to determine if, in the judgement of the person(s) conducting the review, there is the potential for serious or continuing noncompliance. The initial review may be conducted by the RPO Director, RPO Assistant Director(s), an IBC Chair (Associate Chair or Chair), University Biosafety Officer, University Veterinarian or another Institutional Representative. Allegations/indications which are determined to have no potential to be serious and/or continuing noncompliance are resolved with either no follow-up (i.e. when an allegation or indication has no merit) or directly with the PI.

Inquiry/Fact Finding Process: If it is determined that the noncompliance has the potential to be serious or continuing or if questions remain following the initial review, then an inquiry (fact finding) process will begin.  The particular circumstances of the noncompliance will determine when the fact finding begins and when the committee is briefed. The fact finding may be conducted by any IBC designee including a sub-committee or subcommittee member, the RPO Director, Assistant Director(s), an IBC Chair (Associate Chair or Chair) or other Institutional Representatives. The IBC may be briefed at any point throughout the fact finding process, as deemed appropriate by the designee. The fact finding process continues until the designee has arrived at a recommendation of determination (i.e. serious noncompliance and/or continuing noncompliance, or neither). A fact finding report is then prepared and includes the recommendation of determination and draft corrective actions.  This fact finding report will be shared with the PI, and if applicable, other person(s) involved.  All parties will be provided an opportunity to respond to any factual inaccuracies within the report before the committee deliberates.

Deliberation by the IBC: At a convened meeting, the IBC will consider all available information and make a determination as to whether the fact finding revealed serious noncompliance and/or continuing noncompliance, or neither. The following factors will be taken into consideration by the IBC or designee in making their initial determination as to whether the noncompliance is serious and/or continuing noncompliance. As each situation is unique, the indicators of noncompliance that are important in one case may not be relevant in other cases. 

Factors in the Determination of Serious Noncompliance:

  • Level of risk or potential risk to personnel or the environment
  • Severity of safety violation
  • Frequency or number of minor deviations or errors
  • Intent
  • Threat to integrity of the IBC review processes and requirements for the protection of  personnel or the environment (i.e. falsification of IBC documents)
  • Other factors that, in the judgement of the IBC or designee, are relevant to the situation being reviewed.

Factors in the Determination of Continuing Noncompliance: Similarity of noncompliance to previous deviations and/or noncompliance within the same registration or across registrations if the principal investigator has more than one registration.  Likelihood that instances of noncompliance will continue without intervention

Final Determination of the IBC:  If, in the judgement of the committee, the noncompliance is neither serious nor continuing, this determination will be shared with the PI. If, in the judgement of the committee, the noncompliance is serious and/or continuing.  The designee will prepare a summary report including the IBC’s determination and an approved corrective action plan.  This report will be shared with the PI, who will be given 14 days to review it before it becomes final.

Development of Corrective Action Plans:
The IBC/Biosafety Officer/designee will develop a proposed plan for corrective actions based on the information gathered during fact-finding and input from the principal investigator and/or other affected individuals. The proposed plan may:

  • Require no further action
  • Require minor corrective actions to achieve compliance
  • Require additional education
  • Require the investigator and/or other affected individuals to develop and implement procedures to prevent recurrence
  • Review internal departmental or institutional mechanisms and systems for opportunities to prevent recurrence or similar occurrences by others
  • Require additional oversight (e.g., by other faculty member or department process)
  • Require more frequent IBC reviews
  • Require internal monitoring visits or monitoring plans
  • Suspend or terminate individual protocols
  • Restrict researcher’s research activities

Requests for Reconsideration
A PI may request a reconsideration of the IBC’s determination. Requests must be limited to claims that either (1) the process was faulty, resulting in considerable risk that the outcome was incorrect; or (2) that the findings and/or corrective actions imposed by the IBC were excessive or unjustified.  The written request must be submitted within 14 days of receipt of the summary report and must specify the nature of any claimed procedural error or the perceived unfairness of actions taken. Reconsiderations will be conducted by an IBC Chair (Chair or Associate Chair), Biosafety Officer, or Designee.  The reconsideration process will result in one of three outcomes, either the summary report will stand and it will become final, the summary report will be modified and become final, or further investigation is necessary and will be initiated.

Required reporting
When noncompliance is determined to be serious and/or continuing, the final report will be forwarded to federal regulators if required, and to applicable Institutional Officials, the Departmental Chair, the Dean, and sponsors, if applicable.

Guiding Principles for Noncompliance Review

Protection of Personnel and the Environment:  The University of Vermont is committed to minimizing the risks to faculty, staff, students, the public, the facilities, and the environment while using biohazardous materials during research at UVM.

Fairness:   The IBC strives to maintain a review that is impartial and honest, free from self-interest, prejudice or favoritism, including member recusal if such a self-reported or identified conflict arises.   

Communication: The committee will communicate with the PI during the review process at points determined to be appropriate by the IBC designee.

Confidentiality: All IBC discussions and documents regarding a situation of noncompliance are considered sensitive and will be handled in a confidential manner and in accordance with state and federal regulations.  The IBC cannot, however, guarantee complete anonymity to informants or witnesses.  Confidentiality will be maintained to the extent possible to protect privacy and prevent retaliation, while still allowing for a full and fair review. Information may be shared, as described above under Required Reporting.

Conflict of Interest:  Any IBC member who feels that they have a conflicting interest must recuse themselves from reviewing the issue of noncompliance.  IBC members who are also listed as key personnel on the protocol(s) will not participate in the review but may be asked for information.  

Procedures:  In addition to what has been stated within this policy, the Committee will follow all applicable procedures that are outlined within the Committee Operating Procedures document.


Back to Top